News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,592 Results
Type
Article (13851)
Company Profile (102)
Press Release (253639)
Section
Business (88724)
Career Advice (496)
Deals (15474)
Drug Delivery (64)
Drug Development (37456)
Employer Resources (51)
FDA (6410)
Job Trends (6352)
News (151996)
Policy (14160)
Tag
Academia (451)
Alliances (23351)
Alzheimer's disease (395)
Approvals (6432)
Artificial intelligence (85)
Bankruptcy (144)
Best Places to Work (4524)
Breast cancer (71)
Cancer (534)
Cardiovascular disease (50)
Career advice (428)
Cell therapy (81)
Clinical research (31434)
Collaboration (268)
Compensation (108)
COVID-19 (764)
C-suite (84)
Data (512)
Diabetes (67)
Diagnostics (1345)
Drug pricing (59)
Earnings (32041)
Events (38150)
Executive appointments (292)
FDA (6721)
Funding (164)
Gene therapy (79)
GLP-1 (327)
Government (1305)
Healthcare (3662)
Infectious disease (789)
Inflammatory bowel disease (51)
Interviews (62)
IPO (5958)
Job creations (2062)
Job search strategy (383)
Layoffs (182)
Legal (3441)
Lung cancer (83)
Lymphoma (53)
Manufacturing (120)
Medical device (1362)
Medtech (1364)
Mergers & acquisitions (9654)
Metabolic disorders (209)
Neuroscience (541)
NextGen: Class of 2025 (1637)
Non-profit (619)
Northern California (626)
Obesity (124)
Opinion (115)
Patents (77)
People (28853)
Pharmaceutical (65)
Phase I (8231)
Phase II (13305)
Phase III (11902)
Pipeline (260)
Policy (50)
Postmarket research (1423)
Preclinical (3286)
Radiopharmaceuticals (118)
Rare diseases (134)
Real estate (2650)
Regulatory (10084)
Research institute (577)
Resumes & cover letters (58)
Southern California (601)
Startups (1633)
United States (5929)
Vaccines (139)
Weight loss (88)
Date
Today (40)
Last 7 days (268)
Last 30 days (996)
Last 365 days (12856)
2025 (1340)
2024 (12955)
2023 (14684)
2022 (20013)
2021 (20459)
2020 (19408)
2019 (15162)
2018 (11940)
2017 (14132)
2016 (13338)
2015 (15736)
2014 (12563)
2013 (10669)
2012 (11475)
2011 (12009)
2010 (10961)
Location
Africa (315)
Asia (20160)
Australia (2614)
California (1466)
Canada (776)
China (190)
Colorado (59)
Connecticut (56)
Delaware (50)
Europe (39521)
Florida (243)
Illinois (166)
Indiana (111)
Japan (71)
Kansas (53)
Maryland (213)
Massachusetts (1211)
Minnesota (75)
New Jersey (604)
New York (399)
North Carolina (334)
Northern California (626)
Pennsylvania (353)
South America (503)
Southern California (601)
Texas (176)
Virginia (53)
Washington State (100)
267,592 Results for "lb pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in Schizophrenia
January 9, 2025
·
5 min read
Press Releases
LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Mogan Healthcare Conference
January 7, 2025
·
1 min read
Press Releases
UPDATE – LB Pharmaceuticals Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
·
1 min read
Press Releases
Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint
January 22, 2025
·
3 min read
Press Releases
LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment
November 19, 2024
·
4 min read
Press Releases
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
November 27, 2024
·
4 min read
Drug Development
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced online publication of new pre-clinical data in the journal EMBO Reports, showing that its lead compound, LB-100, can turn immunologically “cold” tumors “hot,” potentially enhancing the benefit of immunotherapy.
June 6, 2024
·
4 min read
Press Releases
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
December 10, 2024
·
8 min read
Drug Development
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies.
June 11, 2024
·
5 min read
Biotech Beach
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
LIXTE Biotechnology Holdings, Inc . today provided an update on the Company’s progress with its proprietary compound, LB-100.
March 21, 2024
·
5 min read
1 of 26,760
Next
